Jazz Pharmaceuticals (JAZZ) competitors & alternatives
Health Care · NASDAQ
Jazz Pharmaceuticals (JAZZ)'s top competitors and alternatives — its most similar public companies — include Axsome Therapeutics, Inc. (AXSM), ALKERMES (ALKS), ETON PHARMACEUTCIALS INC (ETON), HARMONY BIOSCIENCES HLDG INC (HRMY), SPRUCE BIOSCIENCES INC (SPRB), AQUESTIVE THERAPEUTICS INC (AQST), LARIMAR THERAPEUTICS INC (LRMR), Ultragenyx (RARE), TRAVERE THERAPEUTICS INC (TVTX), CATALYST PHARMACEUTICALS INC (CPRX), WAVE LIFE SCIENCES LTD (WVE) and SAVARA INC (SVRA). These are Jazz Pharmaceuticals's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top JAZZ competitors & alternatives
-
Axsome Therapeutics, Inc.AXSMHealth Care
A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel…
$239.62 (as of 2026-07-22) · market cap $12.3B
-
ALKERMESALKSHealth Care
Alkermes is a neuroscience-focused biopharmaceutical company commercializing branded therapies for schizophrenia, bipolar disorder, narcolepsy, and substance…
$52.58 (as of 2026-07-22) · market cap $8.8B
-
ETON PHARMACEUTCIALS INCETONHealth Care
Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting…
$43.58 (as of 2026-07-22) · market cap $1.2B
-
HARMONY BIOSCIENCES HLDG INCHRMYHealth Care
Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor…
$34.86 (as of 2026-07-22) · market cap $2.0B
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
AQUESTIVE THERAPEUTICS INCAQSTHealth Care
Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film…
$3.94 (as of 2026-07-22) · market cap $496M
-
LARIMAR THERAPEUTICS INCLRMRHealth Care
Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the…
$4.02 (as of 2026-07-22) · market cap $418M
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
TRAVERE THERAPEUTICS INCTVTXHealth Care
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first…
$56.26 (as of 2026-07-22) · market cap $5.2B
-
CATALYST PHARMACEUTICALS INCCPRXHealth Care
Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from…
$31.49 (as of 2026-07-21) · market cap $3.9B
-
WAVE LIFE SCIENCES LTDWVEHealth Care
A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex…
$5.74 (as of 2026-07-22) · market cap $1.1B
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
Not quite? Describe exactly what you want →
Peers are Jazz Pharmaceuticals's closest public companies by shared sub-industry, sector and business themes. See the full profile: Jazz Pharmaceuticals (JAZZ).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.